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RESUMO – Introdução: Dimensões importantes, tais como experiências pessoais, atitudes em relação à doença, suas causas 
e tratamentos, não são totalmente abordadas em ensaios clínicos. Os Focus Group (FG) surgiram como uma ferramenta inte-
ressante e valiosa na pesquisa clínica, complementando essa lacuna. O objetivo desta pesquisa qualitativa foi avaliar, tanto em 
cuidadores quanto em doentes adultos que lidam com dermatite atópica (DA), as suas atitudes, experiências pessoais e perspe-
tivas em relação à doença e ao seu tratamento tópico, bem como o impacto na qualidade de vida (QV). Material e Métodos: 
Para as sessões de discussão foram recrutados 10 cuidadores e 10 doentes adultos. Foram realizadas duas sessões de FG e 
discutidos três temas principais: perspetivas em relação à DA, tratamentos tópicos e o impacto da doença na QV. Todas as ati-
vidades foram gravadas em vídeo e a discussão e anotações foram transcritas para um documento. A análise posterior foi rea-
lizada por dois investigadores. Resultados: No momento do diagnóstico, os sentimentos vivenciados que melhor o descrevem 
foram “preocupação” (30%) para os cuidadores e “qualidade de vida” (30%) para os doentes. A emoção ou estado de espírito 
"positivo" em relação à doença atual foi "superação" para os cuidadores (21%) e "controlo" para os doentes (17%). A principal 
emoção “negativa ou neutra” foi “medo” para os cuidadores (13%) e “resignação” para os doentes (18%), mas ao projetar para 
a criança doente ao seu cuidado, “frustração” (19%) foi a mais citada pelos cuidadores. Em relação aos tratamentos tópicos, 
a satisfação global média dos cuidadores foi alta (8,5/10) para o tacrolimus, exceto no item “preço”. No caso dos doentes, os 
corticosteroides receberam uma melhor pontuação (8,0/10), com a exceção do item “tolerabilidade/efeitos adversos”. Caracte-
rísticas como “tratamento preventivo com redução das agudizações” e “livre de cortisona” foram importantes para ambos. Todos 
os participantes demonstraram altos níveis de impacto negativo na QV, tendo respetivamente 47% e 64,6% considerado os sco-
res de interferência “bastante” e “muito”. Conclusão: Estudos qualitativos na DA pela metodologia FG são escassos e, do nosso 
conhecimento, este é o primeiro a reunir doentes adultos e cuidadores de crianças. As dimensões obtidas por esta abordagem 
poderão se úteis para complementar os dados dos ensaios clínicos e orientar decisões de investigadores e autoridades de saúde.
PALAVRAS-CHAVE – Criança; Dermatite Atópica; Grupos de Discussão; Inibidores da Calcineurina; Qualidade de Vida.
Atopic Dermatitis: Perspectives and Attitudes of Adult 
Patients and Affected Child Caregivers Assessed by 
Focus Group 
ABSTRACT – Introduction: Important dimensions such as personal experiences, attitudes toward disease, its causes and treat-
ments, are not fully addressed in clinical trials. Focus group (FG) has emerged as an interesting and valuable tool in clinical 
research complementing this gap. The aim of this qualitative research was to assess in both caregivers and patients dealing with 
atopic dermatitis (AD) their attitudes, personal experiences and perspectives toward the disease and its topical treatment as well 
as the impact in quality of life (QoL). Material and Methods: For discussion sessions, 10 caregivers of children and 10 adult 
patients were recruited. Two sessions of FG took place with 3 main themes discussed: perspectives toward AD, topical treatments 
and the impact in QoL. All activities were recorded in video and the discussions and notes were then transcribed to a document, 
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INTRODUCTION
Evidence-based medicine relies mainly on quantitative 
assessments of statistical-significant data drawn mostly from 
clinical trials.1 In general, a high level of objectivity and re-
producibility of the results obtained from these studies, if 
adequately designed, is the rule, in special in terms of effi-
cacy and safety. However, important dimensions such as 
personal experiences, not only from patients but also from 
health care providers and caregivers, attitudes toward di-
sease, its causes and treatments, are not fully addressed 
in clinical trials and a more “medicine-based evidence” is 
required.2 In this setting, focus group (FG) have emerged as 
an interesting and valuable tool in clinical research, com-
plementing not only the quantitative studies but also other 
qualitative approaches such as in-depth interviews and case 
studies.3 In addition, FG are useful to design intervention 
programs in the community for health promotion in a spe-
cific field.4
Atopic dermatitis (AD) is the most prevalent inflamma-
tory skin disease in children and has a chronic, relapsing 
course.5 Although there is a trend to disease improvement 
over time, the patient and their caregivers usually face many 
years of disease activity, which may extend into adulthood. 
The psychosocial impact of the disease assessed by many 
quality of life (QoL) studies clearly transcends the patient 
boundary and involves his family, in special the caregivers.6 
In general, the caregivers are the parents of the affected 
child, in particular the mother. 
Tacrolimus and pimecrolimus belonging to the group of 
topical calcineurin inhibitors (TCIs) have gained an impor-
tant place in the treatment armamentarium of AD.7 These 
compounds represent a pharmacological innovation in the 
last fifty years, during which corticosteroids, the actual gold-
-standard approach, reigned isolated. The role of TCIs, in 
special tacrolimus has been focused not only on disease 
treatment, but also in the prevention of flares, a feature that 
is of paramount importance in a chronic, waved disease 
like AD.8
The aim of this research was to assess attitudes and per-
sonal experiences of both caregivers and patients dealing 
with AD, with a particular regard to the pharmacological 
treatment. In addition, the perspectives of participants to-
ward AD and the impact of the disease in the QoL of both 
groups were also evaluated.
MATERIAL AND METHODS
Participants sampling and pre-sessions data col-
lection
For the discussion sessions, 10 caregivers were recruited, 
8 females and 2 males, with ages ranging from 33 to 45 
years (mean of 38), caring for 12 children suffering from 
AD. The children, 10 males and 2 females, were aged from 
3 months to 11 years (mean of 54.8 months or 4.6 years). 
None of the caregivers suffered from AD.
In addition, 10 adult patients, 8 females and 2 males, 
suffering from AD were also recruited, with ages ranging 
from 22 to 44 years (mean of 34 years).
The diagnosis of AD was confirmed by a dermatologist 
and the severity of the disease was not a pre-session requi-
rement. For both groups of caregivers and patients, expe-
rience in the use of TCIs or other topical pharmacological 
therapies (hydrocortisone base or methylprednisolone) for 
the treatment of AD was also considered, but not the use of 
emollients. 
All participants were informed about the aim of the study 
and written consent was obtained. Any participant received 
financial compensation for their participation, other than 
cost allowances for transportation.
Discussion groups design
Two sessions of FG took place in Spirituc facilities (Spiri-
tuc, - Investigação aplicada, Lda.), in order to offer a rela-
xed environment with a mean duration of two hours each. 
Three main themes were discussed in each session, with the 
following structure:
Theme 1 (caregivers and patients perspectives toward 
AD): in questions 1 (what were the first symptoms or signs, 
which led to a doctor appointment?), 2 (what was the spe-
cialty of the doctor who made the diagnosis?), 3 (after the 
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followed by transcripts analysis. Results: The best descriptive feelings in the moment of diagnosis where “concern” (30%) and 
“quality of life” (30%) for caregivers and patients, respectively. The actual “positive” emotion or state of mind toward the disease 
was “overcoming” for caregivers (21%) and “control” for patients (17%). The main “negative or neutral” emotion was “fear” for 
caregivers (13%) and “resignation” for patients (18%), but when projecting to their child, “frustration” (19%) was the most men-
tioned. In relation to topical treatments, the mean global satisfaction of caregivers was high for tacrolimus (8.5/10), except in 
the item “price”. In the case of patients, corticosteroids received a better score (8.0/10), with exception for “tolerability/adverse 
effects”. Features like “preventive treatment with reduction of flares” and “free of cortisone” were important for both participants 
in an “ideal topical medicine” setting. All participants showed high levels of negative impact in their QoL due to AD, with 47% 
and 64.6% considering scores of “very much” and “a lot” of interference, respectively. Conclusion: Qualitative studies in AD by 
FG are scarce and to our knowledge this is the first one gathering both adult patients and caregivers. The dimensions yielded 
by this approach are useful to complement data retrieved from clinical trials and to drive decisions from researchers and health 
authorities.
KEYWORDS – Calcineurin Inhibitors; Child; Dermatitis, Atopic; Focus Groups; Quality of Life.
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diagnosis by a doctor, did you search further information 
about AD in other sources?), 4 (in which age were the first 
symptoms detected and the diagnosis established?), 5 (what 
phrase better expresses your feelings when facing the diag-
nosis of AD?), all participants were free to answer the topic 
proposed; in question 6 (what are the three states of mind/
emotions, which represent better the actual feeling toward 
the disease?), participants were asked to choose three op-
tions in list of “positive” (“overcoming”, “control”, “tranqui-
lity”, “triumph”) and “negative or neutral” emotions (“fear”, 
“anxiety”, “anger”, “overwhelmed”, “shame”, “frustration”, 
“resignation”). Additionally, in the case of caregivers, along 
with their own emotions, they were asked to choose the sta-
tes of mind/emotions they thought were affecting their child 
(projected emotions).
Theme 2 (Topical treatments): in question 1 (how satis-
fied with the topical treatment) the participants were asked 
to give their satisfaction toward three types of AD treatment: 
the TCIs tacrolimus, pimecrolimus and topical corticoste-
roids (hydrocortisone and methylprednisolone), registering 
the answers in 1 to 10 scale (1- not satisfied; 10- totally 
satisfied). In question 2 (if you could create an “ideal to-
pical medicine” for the treatment of AD, which 5 features 
were the most important?) the participants were asked to 
choose 5 among 10 of the following features randomly pre-
sented: “fast onset but short duration”, “good smell of the 
compound”, “preventive treatment with reduction of flares”, 
“itch relief”, “easy to apply”, “not expensive”, “suitable to be 
applied in any area of the skin”, “more expensive but with 
a long-term efficacy”, “free of cortisone”, “reduced number 
of applications per week”. In question 3 (if it was possible, 
what 3 wishes you made that will improve the QoL in AD?) 
participants were free to mention the 3 wishes.
Theme 3 (Impact of AD in the OoL): for this theme both 
caregivers and patients were asked to score the impact in 
their QoL of several topics (see Tables 3 4  for the list pro-
posed) with the following scale: 1 (nothing/no impact), 2 (a 
little), 3 (a lot) and 4 (very much).
Each group of discussion began with an introduction for 
welcoming the participants, followed by the open-ended 
questions related to the theme used to generate discussion 
(see results section for detailed questionnaire). The facili-
tator, which provided the questions, did not participate in 
the discussion. All activities were recorded in video and the 
discussion was then transcribed to a document, along with 
the facilitator notes, taken during the sessions. Transcripts 
analysis was done by two investigators, one being a der-
matologist, using coding procedures described elsewhere.3
RESULTS
Theme 1 - Caregivers and patients perspectives 
toward AD
Question 1 - What were the first symptoms or 
signs, which led to a doctor appointment?
All 10 caregivers mention that cutaneous xerosis, face 
abrasions, irritation of skin folds and legs were the main 
signs and symptoms, which led them to make a physician 
appointment. However, a higher delay was observed in the 
case of skin dryness, possibly because it was considered a 
“normal” feature in the “fragile” skin of their child.
Similar to caregivers, the patients recall based mainly 
on their parents information, that dryness of the skin, face 
involvement and skin folds irritation were the main signs 
and symptoms. 
Question 2 - What was the specialty of the doctor 
who made the diagnosis?
All caregivers consulted at first a pediatrician. Neverthe-
less, after this first appointment, six were referred to a der-
matologist, one to an allergologist and one maintained the 
follow-up in the pediatrician.
For three patients the dermatologist was the first doctor 
(possibly due to a more late onset of AD, see below) and 
the pediatrician for the remaining. At the time of the focus 
group sessions all patients were in follow-up by a derma-
tologist.
Question 3 - After the diagnosis by a doctor, did 
you search further information about AD in other 
sources?
Although all caregivers stated that they were satisfactory 
enlightened by the information provided by their doctor, the 
internet followed as the second source of information, sear-
ching for topics such as “causes of AD”, “dietary care” and 
“treatment options”, not only conventional therapies but 
also “alternative” approaches, in special “non-pharmaco-
logical”. 
The internet was also the additional source of informa-
tion used by all the patients in their adolescence or adult 
phase, searching mainly for “treatment-related issues”.
Question 4 - In which age were the first symptoms 
detected and the diagnosis stablished?
All caregivers answered that the first months of the first 
year of life of their child, therefore as infant, were the period 
in which the diagnosis of AD was made. 
Seven patients mention also the infant period, but the 
remaining three stated a later onset (2 in childhood, 1 in 
prepuberal period and other as adolescent).
Question 5 - What phrase better expresses your 
feelings when facing the diagnosis of AD?
Forty percent of caregivers mention the term “unknown” 
as the best descriptive of their feelings when they heard the 
diagnosis of AD for the first time (Table  1). In this setting, 
the others where “concern” (30%), “day life limitation” (20%) 
and “blame” (10%). 
In the case of patients, they reported the actual feelings 
regarding the ongoing disease, as “quality of life” (30%), 
“resignation” (30%), “insecurity” (20%), “annoyance” (10%), 
“self-control” (10%) and “confusion” (10%). [Table 1]
Revista SPDV 76(4) 2018; Atopic dermatitis assessed by Focus Group; Alberto Mota.
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Question 6 - What are the three states of mind/
emotions, which represent better the actual feeling to-
ward the disease?
Table  2 summarizes the results for this topic.
Theme 2 – Topical treatments
In relation to topical treatments the following proportion 
was obtained: 9 participants (4 caregivers and 5 patients) 
stated experience with tacrolimus, 5 participants (2 caregi-
vers and 3 patients) with pimecrolimus and 6 participants 
(4 caregivers and 2 patients) with topical corticosteroids.
Question 1 – How satisfied with the topical treat-
ment
For caregivers the mean global satisfaction was high for 
tacrolimus (8.5 in 10), followed by pimecrolimus (7.5) and 
corticosteroids (6.5) [Fig. 1]. Tacrolimus as well pimecrolimus 
were clearly inferior to corticosteroids in the item “price”. In 
the remaining items explored, tacrolimus was superior or simi-
lar to pimecrolimus, with the exception of the “easy to apply”. 
Costicosteroids seems to have a global efficacy similar to 
tacrolimus, in the caregiver’s perspective, but clearly inferior 
in respect to “tolerability/adverse effects”. 
In the case of patients, the “other” treatment (topical corti-
costeroids) received a better score for global satisfaction (8.0), 
followed by tacrolimus (5.2) and pimecrolimus (4.0). [Fig. 1]
Question 2 - If you could create an “ideal topical 
medicine” for the treatment of AD, which 5 features 
were the most important?
Caregivers elected “preventive treatment with reduction 
of flares”, “reduced number of applications per week”, “free 
of cortisone”, “not expensive” and “suitable to be applied in 
any area of the skin” as the main features. Patients mentioned 
“itch relief”, “not expensive”, “easy to apply”, “free of cortiso-
ne” and “reduced number of applications per week”.
Question 3 - If it was possible, what 3 wishes you 
made that will improve the QoL in AD
The caregivers mention in decreasing rank order “to-
pical compound for the prevention of flares”, “total 
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Table 1 - Differences of perceptions between caregivers and patients when facing the diagnosis of AD, 
which may be interpreted as evolving emotions.
What have you felt? 
(caregivers in the moment of diagnosis)
What you actually feel? 
(patients in the moment of focus group)
Unknown	(40%) Evolved	to	Confusion	(10%)
Concern	(30%) Evolved	to	Insecurity	(20%)	/	resignation	(30%)
Limitation	of	day	life	(20%) Evolved	to	Self-control	(10%)	/	loss	of	QoL	(30%)	/	annoyance	(10%)
Blame	(10%)
Table 2 - Actual states of mind/emotions of caregivers and patients in relation to AD. In the case or caregivers, 
they were additionally asked to report what they thought were these emotions in their children (projected).  
“Positive” emotion/state of mind “Negative or neutral” emotion/state of mind
Caregivers 
(own) [%]
Caregivers 
(projected) [%]
Patients (%)
Caregivers 
(own) [%]
Caregivers 
(projected) [%]
Patients (%)
Overcoming 21 7 10 Fear 13 7 0
Control 17 7 17 Anxiety 10 7 3
Tranquility 13 3 10 Anger 3 10 10
Triumph 0 0 3 Overwhelmed 3 17 13
Shame 0 10 3
Frustration 10 19 13
Resignation 10 13 18
Total 51 17 40 Total 49 83 60
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reimbursement” and “greater efficacy of a treatment”. In 
the case of patients, preferences were “oral treatment to 
relieve itch without somnolence”, “treatment free of cortiso-
ne”, “total reimbursement”.
Theme 3 - Impact of AD in the OoL
Tables  3 and 4 summarize the results for this topic.
DISCUSSION
Emerging from marketing analysis, FG have become 
noticeable in recent years as a valuable and reliable tool 
for qualitative analysis in healthcare research, including in 
the field of dermatology.3,9 In fact, by promoting an open 
free but structured discussion between persons sharing a 
common experience, like dealing with a chronic disease 
such as AD, it is possible to assess their attitudes, perspec-
tives, concerns and needs.10 Quantitative studies like clini-
cal trials, although fundamental for clinical research, do 
not always address these dimensions in a suitable manner.2 
Moreover, the conclusions drawn from FG may constitute a 
working base for other exploratory studies and to promote 
projects that will assist decision makers in the health field 
and pharmaceutical companies, among other entities, to 
meet in a more convenient way the real needs of patients, 
caregivers and healthcare agents.11 Atopic dermatitis is the 
most common chronic inflammatory skin disease in chil-
dren with an estimated prevalence of 10% - 20% in this age 
group.5 Although milder cases tend to improve with age, 
more severe presentations may extend into adulthood.12
Theme 1 - Caregivers and patient’s perspectives 
toward AD
It is noteworthy that half of the caregivers had a negative 
view (“concern” and “day life limitation”) about the disease 
and the possible future negative impact on the QoL of their 
child when confronted the diagnosis of AD for the first time. 
However, as adults, the patients demonstrate mixed pers-
pectives, ranging from the ability to live daily with the di-
sease and their difficulties, to the feeling of being unfit and 
unable to cope with the affection. In addition, “insecurity” 
mentioned by 20% of patients reflects the fact that the AD 
itself has an unpredictable course, with unexpected flares 
occurring at any time, which underscores the need of a pre-
ventive treatment (see below). The difference in perception 
in this setting observed between caregivers and patients 
is possibly attributable to different feelings in distinct mo-
ments of this chronic disease, i.e. the impact in the moment 
of the diagnosis (caregivers) and the different ability to cope 
with a disease evolving for years (patients) [see Table  1].
In the case of emotions/state of mind toward AD, it is 
interesting to observe the optimistic view of the caregivers, 
with 51% expressing a “positive” perspective facing the 
disease. However, when projecting the emotions on their 
affected child, the results clearly contrast with the above 
mentioned, as the “negative” view predominates, with 70% 
of the participants considering that their child have a more 
ominous perspective than they do (if discounting “resigna-
tion” as a neutral emotion). This could mean that as ca-
regivers of a child suffering from a chronic disease, they 
are aware of the paramount negative impact of AD in the 
QoL (see below). Consequently, they take a protective at-
titude as their child´s best chance of overcoming difficul-
ties. In the case of patients, there was a more balanced 
perspective between “positive” (40%) and “negative” (41%) 
emotions, possibly reflecting different abilities to cope with 
AD as already discussed. However, it was noteworthy that 
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Figure 1 - Caregivers	and	patients	satisfaction	for	topical	treatments	of	AD,	tacrolimus,	pimecrolimus	and	others	(topical	corticosteroids).	Each	item	was	
scored	using	a	scale	from	1	(not	satisfied)	to	10	(totally	satisfied).
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“resignation” as a “neutral” state of mind predominated 
(18%), expressing a sort of accommodation or adaptation 
to a disease evolving for many years.
Theme 2 - Topical treatment discussions
In caregiver’s perspective the mean global satisfaction 
was high for TCIs, in special for tacrolimus, followed by 
pimecrolimus and topical corticosteroids. However, tacroli-
mus as well pimecrolimus were inferior to corticosteroids in 
the item “price”. Pimecrolimus seemed to be the “easiest to 
apply”, possibly due to its cream consistency, but the oint-
ment formulation of tacrolimus is as expected more potent, 
explaining why this compound is indicated for moderate to 
severe forms of AD.13 Topical corticosteroids, considered the 
gold standard treatment, seemed in fact to have a global 
efficacy similar to tacrolimus, in the caregiver’s perspec-
tive, but clearly inferior in relation to “tolerability/adverse 
effects”. In this respect, the well-known tachyphylaxis14 of 
the corticosteroids and the fear of local and systemic effects 
(“corticophobia”)15 appeared to have played a role. Pa-
tients, on the other hand, demonstrated a less “corticopho-
bic” position, possibly by perceiving a more rapid onset of 
action with these compounds (Fig. 1). Nevertheless, in the 
case of TCIs, tacrolimus maintained superior in most sco-
res in relation to pimecrolimus. Both groups of participants 
shared a vision of a compound that will increase their adhe-
rence to treatment (“not expensive” and “less number of 
applications”) with some degree of “corticoconcern” (“free 
of cortisone”). In fact, phobia to topical corticosteroids is a 
well-known and worldwide phenomenon,15,16 also addres-
sed in FG session.17 In this respect, long-term studies are 
needed to demystify many of the reasons for corticophobia. 
Adult patients focused mainly in the immediate treatment 
of troubled symptoms (“itch relief”) contrasting with care-
givers, which had a more long-term and prophylactic con-
cern, i.e. the prevention of the feared disease exacerbations 
(“preventive treatment with reduction of flares”). Like this 
practical view of adult patients, adolescents also seems to 
Revista SPDV 76(4) 2018; Atopic dermatitis assessed by Focus Group; Alberto Mota.
Table 3 - Impact of several topics in the QoL of caregivers and graded by a scale. Some items reflect an indirect 
impact in QoL as projected in the child.  
Question
Score
1
Nothing 
(%)
2
A little (%)
3
A lot (%)
4
Very much 
(%)
Mean 
score
1. Are you feeling stress caring for your child? 20 20 30 30 2.70
2. Have you sleep disturbances (in quality and number of hours) 
due to caring?
10 50 20 20 2.50
3. How much time you dispend in the treatment? 0 60 20 20 2.60
4. Are you feeling of guilt in relation to your child disease? 0 60 20 20 2.10
5. Do you feel shame by socially exposing your child?
6. (due to fear of mistreatment, neglect or contagiousness)
50 20 30 0 1.80
7. How much did your child feel itch, pain or skin irritation? 0 10 40 50 3.40
8. Did your child feel embarrassment with the skin appearance 50 10 30 10 2.00
9. Did the disease conditioned the garment choice for your child? 0 0 50 50 3.50
10. Did AD affect your social life or leisure time? 20 30 50 0 2.30
11. Did AD affect your physical or sport activity? 20 30 50 0 2.30
12. How much AD interfered with your child attending school or 
kindergarten? *
12.5 87.5 0 0 1.88
13. How much AD interfered in your relationship with friends, col-
leagues or relatives?
0 50 0 10 1.80
14. Did your child care interfered with your daily life activities? 10 50 30 10 2.40
Mean % 14.8 36.6 28.5 18.5
*	The	score	was	only	made	by	80%	of	caregivers	who	mentioned	that	AD	did	not	prevent	the	child	from	attending	school	or	kindergarten.	In	the	remaining	
20%,	10%	considered	that	AD	totally	prevented	the	attendance	and	it	was	not	applicable	to	10%	of	caregivers	(the	child	stayed	all	time	with	caregiver).
405
Artigo Original
share this practical view of adult patients, preferring treat-
ments with a fast and persistent effect, as reported in a 
recent FG study.18 On the other hand, the concern of care-
givers is interesting, just because in recent years has been 
paid more attention not only to the need of early treatment 
of AD exacerbations for better efficacy, but also to the pre-
vention of flares, increasing the disease-free period, an ap-
proach known as proactive treatment.19,20 When AD usually 
relapses on the same locations, it is possible to apply the 
topical drug in a biweekly approach after the improvement 
of the relapse in order to prolong the disease-free state. 
Tacrolimus has been to our knowledge the only topical TCIs 
with demonstrated efficacy in proactive treatment of AD, 
a feature that meets the caregivers expressed needs.8,19-21 
Although this proactive treatment has also been demons-
trated for corticosteroids, like fluticasone and methylpred-
nisolone,22, 23 TCIs, as a drug class, offers some advantages 
over the former, in special the lack of skin atrophy (enabling 
its application in problematic areas, such as the face and 
neck) and tachyphylaxis, reduced skin permeation and an 
efficacy similar to medium-potent corticosteroids, in spe-
cial tacrolimus.24 This could meet the wishes expressed by 
caregivers of a compound “free cortisone”, “suitable to be 
applied in any area of the skin” and of “greater efficacy”.
In both groups of participants, treatment seemed to play 
a major role as a modifier factor of their QoL. As expected 
in a chronic disease, the economic impact of the treat-
ment25,26 cost is present in all participants, a wish that is 
not usually shared by the reimbursement entities (public or 
private). In fact, the level of reimbursement for AD medi-
cations is far for being total and is lower compared with 
other chronic cutaneous diseases, such as psoriasis, a fac-
tor affecting treatment adherence. In fact, low economic 
income and the cost of medicines have been correlated with 
nonadherence to treatment in chronic diseases like AD,27 
which reduce QoL and can increase mortality.28,29 Nonethe-
less, adult patients once again manifest a more short-term 
preoccupation, in special with side effects of treatments 
(“cortisone” and “somnolence”), possibly fearing interfe-
rence of the drugs with their active professions. Caregivers, 
on their side, have a more long-run concern, wishing that a 
more efficacious treatment will also decrease the frequency 
of flares (“prevention”). 
Theme 3 - Impact of AD in the QoL
WHO defines quality of life as “individual’s perception 
of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, 
expectations, standards and concerns”.30 This broad defi-
nition is subject to cultural variability and assessment tools 
need transnational validation. In this work both caregivers 
and patients showed high levels of negative impact in their 
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Table 4 - Impact of several topics in the QoL of patients with AD and graded in a score 1 to 4.  
Question
Score
1
Nothing 
(%)
2
A little (%)
3
A lot (%)
4
Very much 
(%)
Mean 
score
1. How much did you feel itch, pain or skin irritation 0 0 50 50 3.50
2. Did you feel embarrassment with your skin appearance 0 30 30 40 3.10
3. How did AD affect your daily life activities such as shopping, 
home or garden care
0 30 30 40 3.10
4. The choice of your clothing was affected by AD 0 10 50 40 3.30
5. Did AD affect your social life an leisure 0 30 60 10 2.80
6. Did AD affect your physical or sport activity 0 10 50 30 3.00
7. How much the disease affected your work or studies* 0 44 56 0 2.44
8. How much AD interfered in your relationship with friends, col-
leagues or relatives
40 40 20 0 1.80
9. Did AD affect your sexual life 50 50 0 0 1.50
10. Did AD trouble your logistic or took some time of your day 0 10 60 30 3.20
Mean % 9.0 25.4 40.6 24
*	This	question	was	scored	by	90%	of	patients	who	stated	that	the	disease	did	not	prevent	them	to	work	or	study
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QoL due to AD, with 47% and 64.6% considering scores of 
“very much” and “a lot” of interference, respectively (Table 
3 and Table 4). The five items with the highest scores were 
in decreasing rank order “conditioning of garment choice”, 
“level of itch, pain or skin irritation of the child”, “time dis-
pended in caring”, “level of stress in caring” and “sleep dis-
turbances”, in the case of caregivers (Table  3). The patients 
attributed to most items mean scores superior or equal to 3 
(“a lot” or “very much” interference), in which “feeling itch, 
pain or skin irritation”, “choice of clothing”, “time spent on 
the day”, “feelings of embarrassment due to appearance” 
and “interference with daily life activities” with the highest 
scores (Table  4). These results are in good agreement to 
those reported in different QoL assessments for AD.25,26 In 
relation to other chronic diseases, the psychologic impact 
of AD, in special to self-esteem and self-image, seems to 
surpass psoriasis, chronic urticaria, diabetes mellitus and 
arterial hypertension.31,32 Due mainly to pruritus, a negative 
impact in the quality and quantity of sleep is also evident, 
with patients reporting losing a mean of 2 hours by night 
and daytime somnolence with cognitive impairment.33,34 
These disturbances persist even during the remission perio-
ds of inflammation. Also, the presence of notorious levels 
of stress (a well-known flare inducer), anxiety, depression, 
suicidal thoughts, frustration, hypochondria, feelings of 
insecurity, dependence on others and social isolation are 
noted in patients.35-38 In addition, a negative impact of AD 
in the QoL of caregivers and family members in general is 
also reported, turning AD not only an individual affection 
but also a “family” or “social” disease.39 In fact, the presen-
ce of feelings of guilty, shame to expose the child fearing 
misinterpretations of the visible lesions as neglect or mis-
treatment and a negative social and economic impact due 
to high expenses in treatments and clothes, among others, 
have been reported in QoL studies.25,26 Furthermore, in pa-
rallel with this work, most caregivers report high levels of 
stress and time spent in child care, which can be higher 
than those in caring for a child suffering from diabetes me-
llitus, and sleep disturbances as well, increasing the risk of 
unemployment.34,40 
In conclusion, qualitative studies in AD by focus groups 
are scarce and to our knowledge, this is the first one ga-
thering both patients and caregivers of children suffering 
from this common and chronic inflammatory skin disease. 
Although it is not possible to completely rule out biased 
conclusions by this methodology, it is noteworthy that di-
mensions yielded by this approach, such as personal expe-
riences of patients and their attitudes toward disease and 
treatments, are able to complement clinical trials and are 
a source of insights that can drive decisions from pharma-
ceutical researchers and health authorities. In recent years, 
topical TCIs emerged as advantageous alternatives to topi-
cal corticosteroids in AD and its profile meets most of the 
needs of both patients and caregivers reported in this work. 
With a paramount impact in the quality of life, mainly due 
to its chronic course, public health authorities must face AD 
like other chronic skin affections, such as psoriasis, in terms 
of reimbursement of expenditures in efficacious treatments, 
for both adult patients and caregivers of affected children, 
a major concern also addressed in this study.
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